2023年慢性阻塞性肺疾病全球倡议更新评述  

Review of updates 2023 global initiative for chronic obstructive pulmonary disease

作　　者：吴晓娟 杜发旺 罗晓斌[1] 李丽[1] 王小川 王勤[2] 熊伟 朱涛[1] WU Xiaojuan;DU Fawang;LUO Xiaobin;LI Li;WANG Xiaochuan;WANG Qin;XIONG Wei;ZHU Tao(Department of Respiratory and Critical Care Medicine,Suining Central Hospital,Suining 629000,Sichuan,China;Department of Respiratory and Critical Care Medicine,The Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]遂宁市中心医院呼吸与危重症医学科,遂宁四川629000 [2]重庆医科大学附属第二医院呼吸与危重症医学科,重庆410000

出　　处：《西部医学》2024年第1期1-5,共5页Medical Journal of West China

基　　金：国家自然科学基金青年项目(8180011074);四川省自然科学基金(面上项目)(23NSFSC0667);四川省卫生健康委员会科技项目(临床研究专项)(23LCYJ008);中华国际医学交流基金会呼吸疾病青年实用研究项目(Z-2017-24-2301)。

摘　　要：慢性阻塞性肺病(COPD)发病机制复杂,是一种复杂累积和动态的基因-环境-时间相互作用的最终结果,这些相互作用会损害肺部和/或改变其正常的发育。COPD目前是全球范围内发病率和死亡率的主要原因,其经济和社会负担正在不断增加。本文根据2023年慢性阻塞性肺疾病全球倡议(GOLD)的更新,就COPD定义、诊断和治疗等关键问题进行评述,以期为临床医师诊断和治疗COPD患者提供参考和借鉴。Chronic obstructive pulmonary disease(COPD),a chronic disease with complicated pathogenesis,is the end-result of complex,cumulative and dynamic Gene-Environment-Time interactions over the lifetime that can damage the lung and/or alter normal development.COPD is a leading cause of morbidity and mortality worldwide,accounting for heavy economic and social burden which are continuously increasing.In order to provide clinical references for its diagnosis and treatment,this article reviewed the key issues of COPD,including definition,diagnosis,and therapy,which are based on the update of 2023 Global Initiative for Chronic Obstructive Lung Disease(GOLD).

关 键 词：慢性阻塞性肺疾病 GOLD 气流阻塞 药物治疗 病情评估 

分 类 号：R563.9[医药卫生—呼吸系统]